인수 공통 감염증 치료 시장 규모, 점유율, 성장 분석 : 질환 유형별, 치료 유형별, 투여 경로별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)

Zoonotic Disease Treatment Market size was valued at USD 44.23 Billion in 2024 and is poised to grow from USD 46.97 Billion in 2025 to USD 76 Billion by 2033, growing at a CAGR of 6.2% during the forecast period (2026-2033).

Market insights reveal that the incidence of zoonotic diseases transmitted from animals to humans affects a significant number of Americans annually, a concern exacerbated by urbanization and population growth. Poor sanitation in urban areas further heightens this risk. The rising demand for animal proteins may increase the risk of zoonotic infections due to higher consumption of animal fats. Additionally, pet ownership is on the rise, providing companionship but also introducing potential health risks from diseases carried by animals. However, challenges such as limited awareness in developing regions and high R&D costs may hinder market growth. Still, the global zoonotic disease treatment market stands to gain from advancements in novel medications tailored for animal health needs, paving the way for increased investment and innovation.

Top-down and bottom-up approaches were used to estimate and validate the size of the Zoonotic Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Zoonotic Disease Treatment Market Segments Analysis

Global Zoonotic Disease Treatment Market is segmented by Disease Type, Treatment Type, Administration Route, End User and region. Based on Disease Type, the market is segmented into Rabies, Lyme Disease, Zika Virus, West Nile Virus, Hantavirus, Malaria, Tuberculosis, Relapsing Fever, Viral Hepatitis and Others. Based on Treatment Type, the market is segmented into Vaccines, Antiviral Drugs, Antibiotics, Immunoglobulins, Antibacterial Medication, Antifungal Medication and Others. Based on Administration Route, the market is segmented into Intravenous, Intramuscular and Oral. Based on End User, the market is segmented into Hospitals, Ambulatory Surgical Centers, Homecare Settings, Research Institutions and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Zoonotic Disease Treatment Market

The zoonotic disease treatment market is propelled by a variety of factors, including the growing prevalence of zoonotic diseases and heightened awareness regarding their transmission. The introduction of innovative and effective treatment options plays a crucial role in this market's expansion, alongside supportive government initiatives aimed at combating these diseases. Additionally, advancements in technology and a surge in research and development investments significantly contribute to market growth. Together, these elements create a dynamic environment that fosters progress in the treatment of zoonotic diseases, highlighting the urgent need to address the challenges associated with their management and prevention.

Restraints in the Zoonotic Disease Treatment Market

Despite the considerable growth potential in the Zoonotic Disease Treatment market, various challenges could impede progress. Key factors include the limited availability of effective treatment options, prohibitive treatment costs, and insufficient investment in research and development. The advent of generic medications and the expiration of patents on branded drugs may further slow market growth. Additionally, the industry confronts obstacles due to a shortage of skilled professionals and inadequate healthcare infrastructure, particularly in developing countries. High capital requirements for research and development, coupled with a lack of public awareness about zoonotic diseases, pose significant barriers to the market's advancement.

Market Trends of the Zoonotic Disease Treatment Market

The Zoonotic Disease Treatment market is experiencing notable growth, fueled by a surge in global awareness and proactive measures against the rising prevalence of zoonotic diseases. Factors such as urbanization, climate change, and habitat disruption are contributing to the emergence and spread of these diseases, prompting increased investment in research, development, and deployment of innovative treatments and vaccines. Additionally, advancements in biotechnology and genetic engineering are paving the way for more effective therapeutic solutions. As healthcare systems prioritize preventing outbreaks and managing zoonotic disease impacts, the market is poised for significant expansion, fostering collaboration between public health, pharmaceutical, and environmental entities.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Zoonotic Disease Treatment Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Rabies
• Lyme Disease
• Zika Virus
• West Nile Virus
• Hantavirus
• Malaria
• Tuberculosis
• Relapsing Fever
• Viral Hepatitis
• Others

Global Zoonotic Disease Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Vaccines
• Antiviral Drugs
• Antibiotics
• Immunoglobulins
• Antibacterial Medication
• Antifungal Medication
• Others

Global Zoonotic Disease Treatment Market Size by Administration Route & CAGR (2026-2033)

• Market Overview
• Intravenous
• Intramuscular
• Oral

Global Zoonotic Disease Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Homecare Settings
• Research Institutions
• Clinics

Global Zoonotic Disease Treatment Market Size & CAGR (2026-2033)

• North America (Disease Type, Treatment Type, Administration Route, End User)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, Administration Route, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, Administration Route, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, Administration Route, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, Administration Route, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moderna, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations